PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics Announces Poster Presentations at the 2023 American Thoracic Society International Conference

27 Mar 2023 08:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis

13 Mar 2023 08:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results

09 Mar 2023 16:05:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointments of Darren Cline and Thomas McCourt to Board of Directors

08 Mar 2023 16:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

01 Mar 2023 08:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

07 Feb 2023 08:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces FDA Clearance of Investigational New Drug Application for PLN-101095, A Novel Integrin Inhibitor for the Treatment of Solid Tumors

02 Feb 2023 08:02:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

27 Jan 2023 16:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources Officer

25 Jan 2023 08:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public Offering

24 Jan 2023 21:19:04 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Proposed Public Offering of Common Stock

23 Jan 2023 16:01:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis

22 Jan 2023 14:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Receives Orphan Designation from the European Medicines Agency for Bexotegrast (PLN-74809) for the Treatment of Idiopathic Pulmonary Fibrosis

15 Dec 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

15 Nov 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

08 Nov 2022 16:02:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the RBC Biotech Expert Insights Series: Pulmonary/Lung Disease Mini-Symposium

05 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Appointment of Katharine Knobil, M.D. to Board of Directors

15 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

01 Sep 2022 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

30 Aug 2022 08:00:01 By Nasdaq GlobeNewswire